Imaging mass spectrometry of myxoid sarcomas identifies proteins and lipids specific to tumour type and grade, and reveals biochemical intratumour heterogeneity
暂无分享,去创建一个
André M Deelder | Liam A McDonnell | Stefan M Willems | L. McDonnell | P. Hogendoorn | S. Willems | A. Deelder | Pancras C W Hogendoorn | Alexandra van Remoortere | René J M van Zeijl | A. van Remoortere | René van Zeijl | René J. M. van Zeijl
[1] Stefan M Willems,et al. Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and Casein Kinase II inhibition as a potential treatment option , 2010, Molecular Cancer.
[2] L. McDonnell,et al. Peptide and protein imaging mass spectrometry in cancer research. , 2010, Journal of proteomics.
[3] Richard M Caprioli,et al. Molecular analysis of tumor margins by MALDI mass spectrometry in renal carcinoma. , 2010, Journal of proteome research.
[4] M. Clench,et al. Novel molecular tumour classification using MALDI–mass spectrometry imaging of tissue micro-array , 2010, Analytical and bioanalytical chemistry.
[5] H. Shim,et al. Molecular proteomics imaging of tumor interfaces by mass spectrometry. , 2010, Journal of proteome research.
[6] M. Gönen,et al. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. , 2010, The Journal of clinical investigation.
[7] L. Guillou,et al. Soft tissue sarcomas with complex genomic profiles , 2010, Virchows Archiv.
[8] Lisa H Cazares,et al. Imaging Mass Spectrometry of a Specific Fragment of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Kinase 2 Discriminates Cancer from Uninvolved Prostate Tissue , 2009, Clinical Cancer Research.
[9] M. Wiweger,et al. Running GAGs: myxoid matrix in tumor pathology revisited , 2009, Virchows Archiv.
[10] R. Sciot,et al. Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix , 2009, Journal of cellular and molecular medicine.
[11] Richard M Caprioli,et al. Molecular imaging of proteins in tissues by mass spectrometry , 2008, Proceedings of the National Academy of Sciences.
[12] Sören-Oliver Deininger,et al. MALDI imaging combined with hierarchical clustering as a new tool for the interpretation of complex human cancers. , 2008, Journal of proteome research.
[13] J. Lloreta,et al. Genomic Imbalances in Urothelial Cancer: Intratumor Heterogeneity Versus Multifocality , 2008, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[14] Pierre P Massion,et al. High‐throughput proteomic analysis of formalin‐fixed paraffin‐embedded tissue microarrays using MALDI imaging mass spectrometry , 2008, Proteomics.
[15] P. A. Pérez-Mancera,et al. FUS-DDIT3 Prevents the Development of Adipocytic Precursors in Liposarcoma by Repressing PPARγ and C/EBPα and Activating eIF4E , 2008, PloS one.
[16] Peter Tontonoz,et al. Integration of metabolism and inflammation by lipid-activated nuclear receptors , 2008, Nature.
[17] André M Deelder,et al. Mass spectrometry image correlation: quantifying colocalization. , 2008, Journal of proteome research.
[18] Peter Tontonoz,et al. Fat and beyond: the diverse biology of PPARgamma. , 2008, Annual review of biochemistry.
[19] B. Delahunt,et al. Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra‐glandular spread of the initial neoplastic clone , 2008, The Journal of pathology.
[20] Sei Ueda,et al. 中咽頭 myxofibrosarcoma 例 , 2008 .
[21] P. Hogendoorn,et al. Myxoid tumours of soft tissue: the so‐called myxoid extracellular matrix is heterogeneous in composition , 2008, Histopathology.
[22] Michelle L. Reyzer,et al. MALDI imaging mass spectrometry: molecular snapshots of biochemical systems , 2007, Nature Methods.
[23] P. A. Pérez-Mancera,et al. Fat-specific FUS-DDIT3-transgenic mice establish PPARgamma inactivation is required to liposarcoma development. , 2007, Carcinogenesis.
[24] Kornelia Polyak,et al. Breast Tumor Heterogeneity: Cancer Stem Cells or Clonal Evolution? , 2007, Cell cycle.
[25] Gerhard Jakse,et al. Identifying prostate carcinoma by MALDI-Imaging. , 2007, International journal of molecular medicine.
[26] L. Pantanowitz,et al. Myxoid liposarcoma , 2007, Diagnostic cytopathology.
[27] P. Chaurand,et al. Processing MALDI Mass Spectra to Improve Mass Spectral Direct Tissue Analysis. , 2007, International journal of mass spectrometry.
[28] C. Maley,et al. Cancer as an evolutionary and ecological process , 2006, Nature Reviews Cancer.
[29] Richard M. Caprioli,et al. Molecular Assessment of the Tumor Protein Microenvironment Using Imaging Mass Spectrometry , 2006 .
[30] Nicolò Riggi,et al. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. , 2006, Cancer research.
[31] P. Åman,et al. The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells. , 2006, The American journal of pathology.
[32] Carissa A. Sanchez,et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma , 2006, Nature Genetics.
[33] M. Debiec‐Rychter,et al. Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model , 2006, Modern Pathology.
[34] Patrik Edén,et al. Intratumor versus intertumor heterogeneity in gene expression profiles of soft‐tissue sarcomas , 2005, Genes, chromosomes & cancer.
[35] A. Ståhlberg,et al. Myxoid liposarcoma FUS‐DDIT3 fusion oncogene induces C/EBP β‐mediated interleukin 6 expression , 2005, International journal of cancer.
[36] Roy A Jensen,et al. Proteomics in diagnostic pathology: profiling and imaging proteins directly in tissue sections. , 2004, The American journal of pathology.
[37] C. Grommes,et al. Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists , 2004 .
[38] R. Sciot,et al. A phase II trial with rosiglitazone in liposarcoma patients , 2003, British Journal of Cancer.
[39] Michelle L. Reyzer,et al. Direct tissue analysis using matrix-assisted laser desorption/ionization mass spectrometry: practical aspects of sample preparation. , 2003, Journal of mass spectrometry : JMS.
[40] D. Cory,et al. Biochemical correlates of thiazolidinedione‐induced adipocyte differentiation by high‐resolution magic angle spinning NMR spectroscopy , 2002, Magnetic resonance in medicine.
[41] R. Solé,et al. Metapopulation dynamics and spatial heterogeneity in cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[42] M. Itoh,et al. Involvement of the Pro-oncoprotein TLS (Translocated in Liposarcoma) in Nuclear Factor-κB p65-mediated Transcription as a Coactivator* , 2001, The Journal of Biological Chemistry.
[43] G. Fleuren,et al. Allelotype analysis of flow‐sorted breast cancer cells demonstrates genetically related diploid and aneuploid subpopulations in primary tumors and lymph node metastases , 2000, Genes, chromosomes & cancer.
[44] C. Fletcher,et al. Myxoid tumours of soft tissue , 1999, Histopathology.
[45] D. Cory,et al. Classification of human liposarcoma and lipoma using ex vivo proton NMR spectroscopy , 1999, Magnetic resonance in medicine.
[46] Kerry Souza,et al. Correlation of lipid content and composition with liposarcoma histology and grade , 1997, Annals of Surgical Oncology.
[47] M. A. Smith,et al. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. , 1996, The American journal of surgical pathology.
[48] N. Konishi,et al. Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. , 1995, The American journal of pathology.
[49] F. Mitelman,et al. Cytogenetic intratumor heterogeneity in soft tissue tumors. , 1994, Cancer genetics and cytogenetics.
[50] H. Zinszner,et al. A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. , 1994, Genes & development.
[51] N. Mandahl,et al. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma , 1993, Nature.
[52] M. Karas,et al. Matrix-assisted ultraviolet laser desorption of non-volatile compounds , 1987 .
[53] K. Polyak,et al. Tumor heterogeneity: causes and consequences. , 2010, Biochimica et biophysica acta.
[54] C. Grommes,et al. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. , 2004, The Lancet. Oncology.
[55] E. Berg,et al. World Health Organization Classification of Tumours , 2002 .
[56] T. Mentzel. Biological continuum of benign, atypical, and malignant mesenchymal neoplasms - does it exist? , 2000, The Journal of pathology.
[57] F. Collin,et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] C. Cornelisse,et al. Flow cytometric analysis of DNA stemline heterogeneity in primary and metastatic breast cancer. , 1991, Cytometry.